Page Comparison

MSH|^~\&|MOADLEDIT^MOADLEDIT:3.1.2 (Build 6381) [win32-i386]^L|Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|||2016110215051420161019162427+1100||ORU^R01^ORU_R01|XX11021505120XX10191624300-78594735|P|2.4^AUS&Australia&ISO3166_1^HL7AU-OO-201701&&L|||AL|AL|AUS
PID|1||8003608833357361^^^AUSHIC^NI~7654321^^^RMH^MR||CITIZEN^GEORGE||19640701|M|||C/o Paradise Close^^NAR NAR GOON^VIC^3812^AUGOON^VIC^3812^AUS
PV1|1|O|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN
ORC|RE||3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C2890^Unassigned^8D9FE6696165376F222B^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID||CM|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN
OBR|1||3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C2890^Unassigned^8D9FE6696165376F222B^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|8490784908-5^Colorectal3^Prostate Cancer Structured Pathology Report^LNHistopathology^LN||20161019+1100|2016110220161019+1100|||||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN||||LN=3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C28906165376F222B||201611021450201610191609+1100||SPPHY|F||^^^20161102^^^20161019+1100|419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN~921198YF^SMITH^MICHAEL^^^DR^^^AUSHICPR^L^^^UPIN
OBX|1|RP|60572-5^^LN^ENTRY^^EN 13606|1|CEN.RCPA-ColorectalCancer.v3^ColorectalProstateCancer_(Rad_Prostatectomy).v2^Prostate Cancer Structured Pathology ReportHistopathology&99A-4DD10FEE7661CBF6F4ADB3A91A896333&L^TEXT^OctetL^TX^Octet-stream||||||F
OBX|2|CE|70949-3^^LN^CLUSTER^^EN 13606|1.1|70949-3^Clinical details^LN||||||F
OBX|3|ST|5575229306-0^Clinical8^Surgical information^LNprocedure^LN|1.1.12|RRadical Colon cancerprostatectomy||||||F
OBX|4|ST|5772355752-9^Pathology0^Clinical Accession number^LNinformation^LN|1.1.2|89671-16MP4|PCa G6 - prostate and seminal vesicles - left and right pelvic nodes - pre-prostatic fat - left apical margin - left lateral margin||||||F
OBX|5|STNM|220272857-1^Pre-7^Operatingbiopsy surgeonserum name^LNPSA^LN|1.1.3|Dr Dayoub|6|5.9|ug/L^^ISO+|||||F
OBX|6|CEST|33725-3^Tumour location^LNLN-RCPA-00085^Relevant clinical information for clinicopathological staging^L|1.1.7|32713005^Caecum^SCT8|Core biopsy Gleason score: 3+3=6||||||F
OBX|7|CEST|2930657723-8^Type9^Pathology ofaccession operation^LNnumber^LN|1.1.10|235326000^Right hemicolectomy^SCT9|89470-15MP||||||F
OBX|8|ST|8116918600-5^Surgeon's opinion on the existence of local residual cancer postsurgery^LN7^Principal clinician^LN|1.1.1310|NotDr statedSmith||||||F
OBX|9|STCE|LN70949-RCPA-00064^Involvement of adjacent organs^LN3^^LN^CLUSTER^^EN 13606|1.1.14|Not stated2|70949-3^Macroscopic findings^LN||||||F
OBX|10|STNM|LN29638-RCPA-00065^Regional (local) recurrence or distant metastasis^LN|1.1.16|Not stated|4^Specimen weight^LN|1.2.1|60|g^^ISO+|||||F
OBX|11|CE|70949-3^^LN^CLUSTER^^EN 13606|1.2.2|70949-3^Macroscopic findings^LNLN-RCPA-00086^Specimen dimensions (prostate)^L||||||F
OBX|12|NM|LN-RCPA-00066^Specimen length^LN00100^Length^L|1.2.2.1|11351|mm^^ISO+|||||F
OBX|13|CENM|33725-3^Tumour site^LNLN-RCPA-00101^Width^L|1.2.2.2|32713005^Caecum^SCT47|mm^^ISO+|||||F
OBX|14|NM|21889-1^Maximum tumour diameter^LNLN-RCPA-00102^Thickness^L|1.2.2.3|4342|mm^^ISO+|||||F
OBX|15|NMCE|81175LN-RCPA-2^Distance of tumour to the nearer proximal or distal 'cut end'^LN00087^Seminal vesicles^L|1.2.43|35at0196^Present^99A-F4ADB3A91A896333|mm^^ISO+|||||F
OBX|16|NMCE|LN-RCPA-00067^Distance to nonperitonealised circumferential margin^LN00088^Lymph nodes^L|1.2.54|3552101004^Present^SCT|mm^^ISO+|||||F
OBX|17|CE|LN-RCPA-00068^Tumour perforation^LN20228-3^Laterality^LN|1.2.65|2667000^Absent^SCT51440002^Bilateral^SCT||||||F
OBX|18|CE|LN70949-RCPA-00069^Relationship to anterior peritoneal reflection^LN3^^LN^CLUSTER^^EN 13606|1.2.6.7|at0092^Entirely above^99A-4DD10FEE7661CBF61|at0024^Site(s) and numbers of lymph nodes^99A-F4ADB3A91A896333||||||F
OBX|19|CEST|6611239111-4^Lymph nodes^LN0^Site^LN|1.2.6.10|at0224^Received^99A-4DD10FEE7661CBF61.1|Left pelvic||||||F
OBX|20|CENM|70949-3^^LN^CLUSTER^^EN 1360621894-1^Number of LNs from this site^LN|1.3|70949-3^Microscopic findings^LN2.6.1.2|1||||||F
OBX|21|CEST|LN39111-RCPA-00071^Tumour0^Site type^LN2^LN|1.2.36.1.3|35917007^Adenocarcinoma,Right NOS^SCTpelvic||||||F
OBX|22|CENM|33732-9^Histological grade^LN|1.3.2|399415002^Low grade - well and moderately differentiated^SCT21894-1^Number of LNs from this site^LN|1.2.6.1.4|1||||||F
OBX|23|CEST|LN22634-RCPA-00072^Maximum0^Additional degreemacroscopic of local invasion into or through the bowel wall^LN comments^LN|1.32.3|395707006^pT3-Tumour invades through muscularis propria into pericolorectal tissues^SCT8|Volume: 0.6cm3 (3D volume estimate method)||||||F
OBX|24|CE|LN70949-RCPA-00073^Involvement of the proximal/distal resection ('cut end') margins^LN3^^LN^CLUSTER^^EN 13606|1.3.4|at0143^Not involved^99A-4DD10FEE7661CBF670949-3^Microscopic findings^LN||||||F
OBX|25|CE|LN44639-RCPA-00075^Status3^Histological of nonperitonealised circumferential margin (rectal tumours)^LNtumour type^LN|1.3.8|at0241^Not involved^99A-4DD10FEE7661CBF61|45410002^Adenocarcinoma (Acinar, usual type)^SCT||||||F
OBX|26|NMCE|LN70949-RCPA-00076^Microscopic3^^LN^CLUSTER^^EN clearance^LN13606|1.3.9|35|mm^^ISO+4|at0093^Tumour location^99A-F4ADB3A91A896333||||||F
OBX|27|CE|70949-3^^LN^CLUSTER^^EN 13606|1.3.114.14|70949LN-RCPA-3^Lymph00092^Locations nodeby site/s^LNquadrant^L||||||F
OBX|28|STCE|21893-3^Number of positive^LN264176005^Right anterior^SCT|1.3.114.4.1.2|031874001^Yes^SCT||||||F
OBX|29|STCE|21894-1^Total number of lymph nodes^LN277593009^Right posterior^SCT|1.3.114.14.32|1331874001^Yes^SCT||||||F
OBX|30|CE|LN-RCPA-00077^Isolated extra-mural tumour deposits^LN264065008^Left anterior^SCT|1.3.12|2667000^Absent^SCT4.4.3|31874001^Yes^SCT||||||F
OBX|31|CE|LN-RCPA-00078^Apical node involvement^LN277594003^Left posterior^SCT|1.3.13|2667000^Absent^SCT4.4.4|31874001^Yes^SCT||||||F
OBX|32|CE|70949-3^^LN^CLUSTER^^EN 13606|1.3.14|70949-3^Venous and small vessel invasion^LN4.5|LN-RCPA-00090^Locations by plane^L||||||F
OBX|33|CE|LN-RCPA-00079^Intramural vein invasion^LN68756004^Apex^SCT|1.3.4.145.2|at0146^Not identified^99A-4DD10FEE7661CBF61|64100000^No^SCT||||||F
OBX|34|CE|LN-RCPA-00080^Extramural vein invasion^LN279704000^Mid^SCT|1.3.144.5.3|at0149^Not identified^99A-4DD10FEE7661CBF62|64100000^No^SCT||||||F
OBX|35|CE|33739-4^Small36082003^Base vesselof invasion^LNprostate^SCT|1.3.144.5.43|372265000^Present^SCT64100000^No^SCT||||||F
OBX|36|CE|3374170949-0^Perineural3^^LN^CLUSTER^^EN invasion^LN13606|1.3.157|at0156^Not identified^99A-4DD10FEE7661CBF6372278000^Histological tumour grade^SCT||||||F
OBX|37|CENM|LN44641-RCPA-00081^Histologically9^Primary confirmedGleason distant metastases^LNgrade^LN|1.3.167.1|2667000^Absent^SCT3||||||F
OBX|38|CENM|8131744642-0^Relevant7^Secondary coexistantGleason pathological abnormalities^LNgrade^LN|1.3.7.182|260386005^None noted^SCT4||||||F
OBX|39|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4|70949-3^Ancillary test findings^LN385432009^Tertiary Gleason grade not applicable^SCT|1.3.7.4|64100000^No^SCT||||||F
OBX|40|FT|35266-6^Gleason score^LN^372278000^^SCT|1.3.7.5|3+4=7\.br\Composite Gleason Score (ISUP) 2005): 3+4=7 \.br\Index carcinoma score (ISUP 2005): 3+4=7 % \.br\High Grade (4/5): 5%. \.br\Intraduct carcinoma: Absent.||||||F
OBX|41|CE|LN-RCPA-00096^Extent^L|1.3.9|420366008^Focal^SCT||||||F
OBX|4042|CE|70949-3^^LN^CLUSTER^^EN 13606|1.43.110|70949-3^Mismatch repair enzymes^LNLN-RCPA-00095^Location(s) of EPE^L||||||F
OBX|43|CE|at0138^Lateral^99A-F4ADB3A91A896333|1.3.10.1|64100000^No^SCT||||||F
OBX|4144|CE|50328at0139^Postero-4^PMSlateral^99A-2^LNF4ADB3A91A896333|1.43.110.2|at0195^Normal staining^99A-4DD10FEE7661CBF6|64100000^No^SCT||||||F
OBX|45|CE|at0140^Posterior^99A-F4ADB3A91A896333|1.3.10.3|64100000^No^SCT||||||F
OBX|4246|CE|50324-3^MSH-6^LN|1.4.1.4|at0201^Normal staining^99A-4DD10FEE7661CBF6at0141^Anterior^99A-F4ADB3A91A896333|1.3.10.4|64100000^No^SCT||||||F
OBX|47|CE|at0142^Bladder neck^99A-F4ADB3A91A896333|1.3.10.5|64100000^No^SCT||||||F
OBX|48|CE|at0143^Apical^99A-F4ADB3A91A896333|1.3.10.6|64100000^No^SCT||||||F
OBX|49|CE|at0144^Other^99A-F4ADB3A91A896333|1.3.10.7|64100000^No^SCT||||||F
OBX|4350|CE|4336844670-0^Microsatellite instablility (MSI)^LN8^Margin status^LN|1.4.1.6|373121007^Not tested^SCT3.11|55182004^Not involved^SCT||||||F
OBX|51|CE|44626-0^Seminal vesicles^LN|1.3.16|at0160^Not involved^99A-F4ADB3A91A896333||||||F
OBX|4452|CE|5848370949-9^BRAF (V600E mutation)^LN3^^LN^CLUSTER^^EN 13606|1.4.1.9|at0208^Not tested^99A-4DD10FEE7661CBF63.19|23.02.28965^Lymph node status^RCPA||||||F
OBX|53|NM|44621-1^Number of lymph nodes examined^LN|1.3.19.1|1||||||F
OBX|4554|CENM|2170321893-4^RAS3^Number of genepositive mutationlymph testing^LNnodes^LN|1.3.4.1.12|373121007^Not tested^SCT19.2|0||||||F
OBX|55|CE|59544-7^Lymphovascular invasion^LN|1.3.20|at0171^Not identified^99A-F4ADB3A91A896333||||||F
OBX|4656|CE|70949-3^^LN^CLUSTER^^EN 13606|1.54|70949-3^Synthesis and overview^LN||||||F
OBX|4757|CE|70949-3^^LN^CLUSTER^^EN 13606|1.54.1|21902-2^Tumour2^Pathological stagestaging (AJCC 20107th Ed)^LN||||||F
OBX|4858|CE|21899-0^T classification^LN0^Primary tumour (T)^LN|1.54.1.1|395707006^pT3^SCTat0176^T2  Organ Confined^L||||||F
OBX|4959|CE|2190070949-6^N3^^LN^CLUSTER^^EN classification^LN13606|1.5.1.2|at0292^pN0^L4.2|67203-0^Year and edition of staging system^LN||||||F
OBX|60|ST|at0106^Year^99A-F4ADB3A91A896333|1.4.2.1|AJCC 2005||||||F
OBX|5061|CEST|LN-RCPA-00084^Residual tumour status^LNat0107^Edition^99A-F4ADB3A91A896333|1.4.52.2|at0212^R0^99A-4DD10FEE7661CBF67th Ed||||||F
OBX|5162|FT|2263734574-3^Diagnostic4^Diagnostic summary^LN|1.54.3|Diagnostic summary:1. Radical prostatectomy: Prostatic adenocarcinoma \.br\Speciment type: Right hemicolectomy2. Left pelvic lymph node: Fibradipose tissue only \.br\Tumour site: Caecal\.br\Tumour type: Adenocarcinoma\.br\Tumour stage: T3 N0 MX3. Right pelvic lymph node: No evidence of malignancy \.br\Completeness4. ofPeriprostatic excisiontissue: Completely excised No evidence of malignancy \.br\Diagnosis:\.br\Right Colon - Moderately differentiated caecal Adenocarcinoma, T3\.br\Thirteen lymph nodes negative for metastatis (0/13)\.br\Surgical margins clear5. Left apical margin: No evidence of mailgnancy 6. Left lateral margin: No evidence of malignancy||||||F
OBX|52|ED|PDF^Display format in PDF^AUSPDI||ECLIPSE&ECLIPSE:3.1.8 [win32-i386]&L^application^pdf^Base64^JVBER...g0K||||||F